Creatine Safety and Tolerability in Premanifest HD: PRECREST.

Trial Profile

Creatine Safety and Tolerability in Premanifest HD: PRECREST.

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs Creatine monohydrate (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms PRECREST
  • Most Recent Events

    • 07 Feb 2014 Actual patients number changed from 67 to 64 as reported by
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by
    • 25 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Aug 2013 as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top